Medtronic Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Medtronic şirketinin kazançları yıllık ortalama -2.6% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 12% oranında artan oldu. Gelirler yıllık ortalama 2.3% oranında artan oldu. Medtronic şirketinin öz sermaye getirisi 8.9% olup, net marjı 13% dir.

Anahtar bilgiler

-2.6%

Kazanç büyüme oranı

-2.2%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	8.9%
Gelir büyüme oranı	2.3%
Özkaynak getirisi	8.9%
Net Marj	13.0%
Sonraki Kazanç Güncellemesi	18 Feb 2025

Yakın geçmiş performans güncellemeleri

Recent updates

An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 33% Undervalued

Sep 30

Medtronic (NYSE:MDT) Boosts FY 2025 Guidance Amid Strong Q1 Earnings and Strategic Share Buybacks

Sep 16

Medtronic: An Undervalued Stock With Durable Competitive Advantages

Sep 16

Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly

Sep 05

Medtronic: Is The Company Back?

Aug 26

Medtronic: Still A Buy Before Earnings

Aug 17

Returns At Medtronic (NYSE:MDT) Appear To Be Weighed Down

Aug 08

Medtronic: An Out Of Favor Healthcare Stock With A Pulse On Profit Potential

Jul 16

At US$77.06, Is Medtronic plc (NYSE:MDT) Worth Looking At Closely?

Jul 11

Medtronic (NYSE:MDT) Is Paying Out A Larger Dividend Than Last Year

Jun 27

Medtronic: Why I Disagree With The Crowd

Jun 14

Medtronic's (NYSE:MDT) Upcoming Dividend Will Be Larger Than Last Year's

Jun 10

Medtronic: Net Income Could Fall $3.38B, The Stock Would Still Be Undervalued

May 27

Medtronic (NYSE:MDT) Has Announced That It Will Be Increasing Its Dividend To $0.70

May 26

These 4 Measures Indicate That Medtronic (NYSE:MDT) Is Using Debt Reasonably Well

May 22

Medtronic Stock Looks Promising Before Fiscal Q4 2024 Release

May 13

Is Medtronic plc (NYSE:MDT) Trading At A 20% Discount?

May 01

35% Undervalued? Medtronic's Future Looks Very Bright

Apr 12

Medtronic: Buy This Dividend Aristocrat Diamond In The Rough Now

Mar 27

Medtronic: Undervalued Medical Devices Stock With Robust Demand And Strong Dividend Growth

Mar 11

Medtronic (NYSE:MDT) Has Announced A Dividend Of $0.69

Mar 11

Medtronic: Its Recent Beat Proves That It Continues To Be A Rock

Feb 25

Results: Medtronic plc Beat Earnings Expectations And Analysts Now Have New Forecasts

Feb 22

Medtronic: A Good Choice For Dividend Investors Seeking For Low Volatility

Feb 16

A Look At The Fair Value Of Medtronic plc (NYSE:MDT)

Jan 31

Does Medtronic (NYSE:MDT) Have A Healthy Balance Sheet?

Jan 16

Medtronic Stock's Rally Is Set To Continue

Jan 11

Medtronic plc's (NYSE:MDT) Price Is Out Of Tune With Earnings

Dec 29

Medtronic's (NYSE:MDT) Dividend Will Be $0.69

Dec 12

Medtronic: The GLP-1 Drug Headwinds Are Overblown

Dec 10

3.5% Yield And Over 15% Annual Return Potential - I Really Like Medtronic

Nov 28

Returns On Capital At Medtronic (NYSE:MDT) Have Hit The Brakes

Nov 19

Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings

Nov 17

Medtronic Faces Potential Decline Despite Financial Strength

Oct 29

An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 21% Undervalued

Oct 19

Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly

Oct 04

Medtronic: Improved Guidance, Historically Cheap P/E, Yield Reaches 3.5%

Sep 27

Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69

Sep 18

Gelir ve Gider Dağılımı

Medtronic nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NYSE:MDT Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
25 Oct 24	32,996	4,288	10,258	2,743
26 Jul 24	32,577	3,927	10,243	2,743
26 Apr 24	32,364	3,676	10,183	2,735
26 Jan 24	32,320	4,201	10,204	2,702
27 Oct 23	31,958	4,102	10,135	2,694
28 Jul 23	31,558	3,620	10,064	2,672
28 Apr 23	31,227	3,758	10,004	2,696
27 Jan 23	30,771	4,064	11,825	2,707
28 Oct 22	30,806	4,321	11,749	2,688
29 Jul 22	31,070	5,205	11,744	2,688
29 Apr 22	31,686	5,039	10,047	2,746
28 Jan 22	31,785	4,914	10,015	2,726
29 Oct 21	31,798	4,704	9,957	2,659
30 Jul 21	31,597	3,882	9,997	2,622
30 Apr 21	30,117	3,606	9,956	2,493
29 Jan 21	27,926	2,892	9,543	2,429
30 Oct 20	27,868	3,537	9,661	2,401
31 Jul 20	27,927	4,412	9,644	2,365
24 Apr 20	28,913	4,789	9,882	2,331
24 Jan 20	31,062	5,408	11,857	2,357
25 Oct 19	30,891	4,762	11,889	2,345
26 Jul 19	30,666	4,420	10,105	2,332
26 Apr 19	30,557	4,631	10,273	2,330
25 Jan 19	30,555	4,826	11,912	2,328
26 Oct 18	30,378	2,168	11,844	2,326
27 Jul 18	29,947	3,163	9,963	2,292
27 Apr 18	29,953	3,104	10,077	2,256
26 Jan 18	29,725	2,859	11,993	2,217
27 Oct 17	29,639	5,069	11,878	2,188
28 Jul 17	29,934	4,115	9,813	2,186
28 Apr 17	29,710	4,028	9,715	2,193
27 Jan 17	29,361	3,968	9,592	2,215
28 Oct 16	29,012	4,242	9,521	2,231
29 Jul 16	28,725	3,647	9,448	2,222
29 Apr 16	28,833	3,538	9,469	2,224
29 Jan 16	28,435	2,434	9,513	2,177
30 Oct 15	25,819	2,316	8,683	2,004
31 Jul 15	23,127	2,624	7,847	1,833
24 Apr 15	20,261	2,675	6,904	1,640
23 Jan 15	17,410	3,124	6,039	1,497
24 Oct 14	17,255	2,909	6,006	1,484
25 Jul 14	17,083	2,983	5,937	1,482
25 Apr 14	16,893	3,065	5,847	1,477
24 Jan 14	16,879	3,586	5,783	1,501

Kaliteli Kazançlar: MDT yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: MDT 'nin mevcut net kar marjları (13%) geçen yılın (12.8%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: MDT şirketinin kazançları son 5 yılda yılda 2.6% oranında azaldı.

Büyüme Hızlandırma: MDT 'un son bir yıldaki kazanç büyümesi ( 4.8% ) 5 yıllık ortalamasını (yıllık -2.6% ) aşıyor.

Kazançlar vs. Sektör: MDT geçen yılki kazanç büyümesi ( 4.8% ) Medical Equipment sektörünün 10.4% performansını geride bırakmadı.

Özkaynak Getirisi

Yüksek ROE: MDT 'nin Özsermaye Getirisi ( 8.9% ) düşük olarak değerlendiriliyor.

Medtronic Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First quarter 2025 earnings: EPS exceeds analyst expectations

Full year 2024 earnings: EPS misses analyst expectations

Full year 2024 earnings: EPS misses analyst expectations

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025

Second quarter 2024 earnings: EPS misses analyst expectations

Recent updates

Medtronic plc Receives FDA Clearance for New Inpen App, Pending the Way for Its Smart MDI System Launch with Simplera™? CGM

New minor risk - Earnings quality

Medtronic Q3 Earnings: A Solid Performance, But Bottom Line Still Needs Fixing

Medtronic (NYSE:MDT) Hasn't Managed To Accelerate Its Returns

CMS Grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral Renal Denervation Catheter

Medtronic: Undervalued But Trapped In Slow Growth (Rating Downgrade)

Medtronic plc Announces New, Long-Term Data from Its SPYRAL HTN-ON MED Clinical Trial

Medtronic plc Receives FDA Approval of Affera Mapping and Ablation System and Sphere-9 Catheter

Is It Time To Consider Buying Medtronic plc (NYSE:MDT)?

Medtronic: Undervalued Dividend Aristocrat With High Margins

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc Announces the Presentation of Clinical Study Results

An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 33% Undervalued

Upcoming dividend of US$0.70 per share

Medtronic (NYSE:MDT) Boosts FY 2025 Guidance Amid Strong Q1 Earnings and Strategic Share Buybacks

Medtronic: An Undervalued Stock With Durable Competitive Advantages

Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly

Consensus EPS estimates increase by 12%

Medtronic: Is The Company Back?

First quarter 2025 earnings: EPS exceeds analyst expectations

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2025

Fourth quarter dividend of US$0.70 announced

Medtronic: Still A Buy Before Earnings

Medtronic plc Announces Cash Dividend for Second Quarter of Fiscal Year 2025, Payable on October 11, 2024

Medtronic plc, Annual General Meeting, Oct 17, 2024

Returns At Medtronic (NYSE:MDT) Appear To Be Weighed Down

Medtronic: An Out Of Favor Healthcare Stock With A Pulse On Profit Potential

At US$77.06, Is Medtronic plc (NYSE:MDT) Worth Looking At Closely?

Now 25% undervalued after recent price drop

New minor risk - Earnings quality

Now 20% undervalued after recent price drop

Medtronic plc Announces Resignation of Karen Parkhill as CFO

Medtronic (NYSE:MDT) Is Paying Out A Larger Dividend Than Last Year

Medtronic plc Announces Resignation of Karen Parkhill as CFO

Full year 2024 earnings: EPS misses analyst expectations

Medtronic: Why I Disagree With The Crowd

Chairman of the Board & CEO notifies of intention to sell stock

Medtronic's (NYSE:MDT) Upcoming Dividend Will Be Larger Than Last Year's

Medtronic plc Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024

Consensus EPS estimates fall by 10%

Medtronic: Net Income Could Fall $3.38B, The Stock Would Still Be Undervalued

Medtronic (NYSE:MDT) Has Announced That It Will Be Increasing Its Dividend To $0.70

Full year 2024 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 10%

Medtronic plc Increases Cash Dividend for the First Quarter of Fiscal Year 2025, Payable on July 12, 2024

These 4 Measures Indicate That Medtronic (NYSE:MDT) Is Using Debt Reasonably Well

Medtronic plc Announces its Investigational OmniaSecure Defibrillation Lead Met its Primary Safety and Effectiveness Endpoints, Existing Safety and Effectiveness Endpoints

Medtronic Stock Looks Promising Before Fiscal Q4 2024 Release

Is Medtronic plc (NYSE:MDT) Trading At A 20% Discount?

Medtronic plc Receives FDA Approval for Inceptiv Closed-Loop Spinal Cord Stimulator

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

35% Undervalued? Medtronic's Future Looks Very Bright

Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO

Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut™ Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women

Medtronic: Buy This Dividend Aristocrat Diamond In The Rough Now

Upcoming dividend of US$0.69 per share

Medtronic: Undervalued Medical Devices Stock With Robust Demand And Strong Dividend Growth

Medtronic (NYSE:MDT) Has Announced A Dividend Of $0.69

Third quarter dividend of US$0.69 announced

Medtronic plc Presents New Clinical and Real-World Data on the MiniMed™ 780G System from Around the World

Medtronic plc Approves Cash Dividend for the Fourth Quarter of Fiscal Year 2024, Payable on April 12, 2024

Medtronic: Its Recent Beat Proves That It Continues To Be A Rock

Insider notifies of intention to sell stock

Results: Medtronic plc Beat Earnings Expectations And Analysts Now Have New Forecasts

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Medtronic: A Good Choice For Dividend Investors Seeking For Low Volatility

Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025

A Look At The Fair Value Of Medtronic plc (NYSE:MDT)